Boston Partners Buys 11,738 Shares of Haemonetics Corporation $HAE

Boston Partners lifted its stake in shares of Haemonetics Corporation (NYSE:HAE) by 2.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 543,169 shares of the medical instruments supplier’s stock after purchasing an additional 11,738 shares during the period. Boston Partners owned 1.13% of Haemonetics worth $40,660,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in HAE. Dynamic Technology Lab Private Ltd acquired a new stake in Haemonetics in the first quarter valued at $468,000. AQR Capital Management LLC increased its stake in shares of Haemonetics by 591.6% during the 1st quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock worth $10,931,000 after purchasing an additional 149,325 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Haemonetics by 7.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,907 shares of the medical instruments supplier’s stock valued at $963,000 after purchasing an additional 898 shares during the period. Royal Bank of Canada lifted its stake in Haemonetics by 2.3% in the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock valued at $68,355,000 after purchasing an additional 24,650 shares during the last quarter. Finally, Invenomic Capital Management LP bought a new position in Haemonetics during the first quarter worth about $6,783,000. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on HAE shares. Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Needham & Company LLC lifted their price objective on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Raymond James Financial reissued an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Finally, Mizuho reduced their target price on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.70.

Haemonetics Stock Performance

Shares of NYSE:HAE opened at $80.67 on Friday. The company’s 50 day moving average price is $57.96 and its two-hundred day moving average price is $63.31. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $89.69. The firm has a market cap of $3.78 billion, a PE ratio of 24.67, a PEG ratio of 0.91 and a beta of 0.43. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.